Genetic and Congenital

Continued use of burosumab in X-linked hypophosphatemia needed to sustain clinical benefit

To sustain clinical benefit from treatment with burosumab in X-linked hypophosphatemia (LH), long-term, continued use appears to be needed, according to results from a Phase 3 open-label extension trial. In this study, 31 patients from a 96-week phase 3 study continue treatment on a burosumab regimen for a further 48...